Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

p> Therapeutics Inc. - - 2,156,685

Gain on sale of BCY

LifeSciences Inc. - - (299,403)

Cancellation of contingent

payment obligation settled

in common shares - - 150,000

Future income tax recovery - - (1,115,000)

-------------------------------------------------------------------------

- - 1,383,537

-------------------------------------------------------------------------

-------------------------------------------------------------------------

6. CAPITAL DISCLOSURES

The Company's objective when managing capital is to maintain adequate

cash resources to support planned activities which include the clinical

trial program, product manufacturing, administrative costs and

intellectual property expansion and protection. The Company includes

shareholders' equity, cash and short-term investments in the definition

of capital. The Company does not have any debt other than trade accounts

payable and has potential contingent obligations relating to the

completion of its research and development of REOLYSIN(R).

In managing capital, the Company estimates its future cash requirements

by preparing a budget and a multiyear plan annually for review and

approval by the Company's board of directors (the "Board"). The budget

establishes the approved activities for the upcoming year and estimates

the costs associated with these activities. The multiyear plan estimates

future activity along with the potential cash requirements and is based

on the Company's assessment of its current clinical trial progress along

with the expected results from the coming year's activity. Budget to

actual variances are prepar
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... solutions for drug discovery and related life ... consortium has chosen Genedata Selector as its ... (NGS) data. FUNGITECT is a European consortium ... fungal diseases via individualized anti-fungal drug therapies. ...
(Date:9/30/2014)... CORALVILLE, Iowa , Sept. 30, 2014 /PRNewswire/ ... in the discovery and development of proprietary new ... United States Patent and Trademark Office (USPTO) issued ... patent application entitled, "Benzoic Acid, Benzoic Acid Derivatives ... Methods of Making and Use Thereof." ...
(Date:9/30/2014)... MAR, Calif. , Sept. 30, 2014 ... for women,s health announces its receipt of a patent ... FemmyCycle menstrual cup has also received FDA clearance in ... Canada, and the CE in Europe. This patent is related ... conjunction with this issuance, the company is releasing FemmyCycle ...
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... analyze global next-generation (NGS) sequencing trends and use. ... technology use is expected to increase within the ... are the top criteria for purchasing sequencing instruments. ... technologies. The popularity of RNA-Seq continues to surge, ...
Breaking Biology Technology:FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2The FemmyCycle 2Global Next-generation Sequencing Trends 2
... ATLANTA, Nov. 6, 2010 Alder Biopharmaceuticals Inc. today announced ... antibody therapeutic will be presented at the Annual Meeting of ... continue to be encouraged about the clinical data from the ... for the first time, from our Phase 1 study of ...
... Inc. (Nasdaq: CLRT ) announced today that its ... stockholders tender their shares to General Electric Company (NYSE: ... per share of Clarient,s common stock and $20.00 per share ... transaction is expected to close during the fourth quarter of ...
... CAMBRIDGE, Mass., Nov. 5, 2010 Metamark Genetics, Inc., ... the appointment of Mark R. Straley as the company,s ... Board of Directors. Kenneth E. Weg, a Metamark co-founder ... serve as Chairman of the Board of Directors. ...
Cached Biology Technology:Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology 2Clarient's Board of Directors Recommends Stockholders Accept General Electric's Cash Tender Offer 2Clarient's Board of Directors Recommends Stockholders Accept General Electric's Cash Tender Offer 3Clarient's Board of Directors Recommends Stockholders Accept General Electric's Cash Tender Offer 4Metamark Genetics, Inc. Announces New Chief Executive Officer 2
(Date:9/29/2014)... culture, mathematics is often deemed inaccessible or esoteric. Yet ... important role in our daily lives and a decisive ... often behind the scenes. , UC Santa Barbara,s ... and an assistant professor of mechanical engineering, often works ... his recent research published in the Proceedings of ...
(Date:9/29/2014)... of dinosaurs, gigantic reptilesdistant relatives of modern crocodilesruled the ... and it was thought they didn,t much interact. But ... researcher in the thigh of one of these ancient ... an earth and planetary sciences lecturer, and her Virginia ... bite marks in the thigh bones of an old ...
(Date:9/29/2014)... , Canda, September 29, 2014 ... as UID Coupled with Increasing Security Concerns Continue ... India is one of ... increasing adoption of biometrics systems, majorly in various ... NREGA, etc. Fingerprint modality based biometrics dominates the ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4Tooth serves as evidence of 220 million-year-old attack 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3
... Through a collaborative genome-wide study on individuals, researchers ... with heart rate. Since heart rate is a ... better understanding of genetic regulation of heart beat and ... drugs to treat cardiovascular disease. The study, titled, ...
... can keep clogged leg arteries open, preventing amputation ... the Society of Interventional Radiology,s 38th Annual Scientific ... (or PAD) is becoming increasingly prevalent due to ... epidemics," said Robert A. Lookstein, M.D., FSIR, lead ...
... WEST ORANGE, N.J.The State of Spinal Cord Injury: Latest ... Recovery will be held on Wednesday, April 17, 2013, ... Pleasant Valley Way, West Orange, N.J. This special Grand ... Cord Injury System (NNJSCIS) and the Spinal Cord Injury ...
Cached Biology News:Mount Sinai study identifies new gene variations associated with heart rate 2Drug-coated stents prevent leg amputation 2The State of Spinal Cord Injury Grand Rounds 2
Prepared from plasminogen by activation with immobilized human uPA...
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Biology Products: